MUMBAI, India, July 29, 2025 /PRNewswire/ — Tata Communications, a leading global communications technology player, in collaboration with Amazon Web Services (AWS), an Amazon.com, Inc. company, announced that the companies will enable an advanced AI-ready network in India. The strategic collaboration will establish a high-capacity, resilient long-distance network connecting three major AWS infrastructure locations to bolster generative AI adoption and cloud innovation in India.

The collaboration marks one of the India’s largest ever network deployments by Tata Communications in terms of size, scale and bandwidth. AWS has two data centre regions in India located in Mumbai and Hyderabad, and AWS Direct Connect and AWS Edge Network infrastructure in Chennai. The network will connect AWS infrastructure in Mumbai, Hyderabad, and Chennai through a comprehensive, national long-haul network, creating a powerful infrastructure backbone for AI and machine learning (ML) workloads across India.

Key highlights of the partnership:

• Next-Generation Network Connectivity: Leverage Tata Communications’ state-of-the-art network to provide high-bandwidth, low-latency connections essential for AI workloads. AWS will continue to deploy its custom network technologies on this network, enabling industry-leading security, availability, and performance between AWS locations
• Enablement of AI-Powered Applications: Further enable businesses across India to build, train, and deploy scalable AI applications, fostering innovation in sectors like healthcare, finance, and education
• Commitment to Security and Compliance: Ensure robust security measures and adhere to regulatory standards to protect data integrity and privacy

The new network will help provide leading network performance and scalability that are critical for next-generation AI applications. By leveraging Tata Communications state-of-the-art network, AWS will further empower Indian businesses to develop Gen AI applications and train AI models, with unprecedented speed and efficiency. The network will feature express routes with ultra-low latency, helping ensure seamless data transfer and processing capabilities essential for compute-intensive AI and ML workloads.

“This association marks our largest ever National Long-Distance program and showcases Tata Communications’ unparalleled capability to support large-capacity, complex projects requiring scaled network solutions,” said Genius Wong, Executive Vice President, Core and Next-Gen Connectivity Services and Chief Technology Officer, Tata Communications. “AI is transforming industries globally, and our collaboration with AWS positions us at the forefront of this revolution in India. Together, we’re enabling a network that not only meets the current demands but anticipates the needs of tomorrow. By building a tailored network solution we’re ushering in an AI era in India, reinforcing our position as the long-term partner of choice for global technology leaders.”

“We are excited to work with Tata Communications to establish an advanced in-country network in India,” said Jesse Dougherty, Vice President for Network Edge Services at Amazon Web Services. “The infrastructure is designed to support the most data intensive workloads, like 5G, generative AI, and high-performance computing. This collaboration with Tata Communications will further enable our customers in India to innovate at scale with cloud and generative AI, and drive growth in India’s rapidly expanding digital economy.”

About Tata Communications

A part of the Tata Group, Tata Communications (NSE: TATACOMM) (BSE: 500483) is a global digital ecosystem enabler powering today’s fast-growing digital economy in more than 190 countries and territories. Leading with trust, it enables digital transformation of enterprises globally with collaboration and connected solutions, core and next gen connectivity, cloud hosting and security solutions and media services. 300 of the Fortune 500 companies are its customers and the company connects businesses to 80% of the world’s cloud giants. For more information, please visit www.tatacommunications.com

X | LinkedIn | YouTube | Instagram

Forward-looking and cautionary statements

Certain words and statements in this release concerning Tata Communications and its prospects, and other statements, including those relating to Tata Communications’ expected financial position, business strategy, the future development of Tata Communications’ operations, and the general economy in India, are forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors, including financial, regulatory, and environmental, as well as those relating to industry growth and trend projections, which may cause actual results, performance or achievements of Tata Communications, or industry results, to differ materially from those expressed or implied by such forward-looking statements. The important factors that could cause actual results, performance or achievements to differ materially from such forward- looking statements include, among others, failure to increase the volume of traffic on Tata Communications’ network; failure to develop new products and services that meet customer demands and generate acceptable margins; failure to successfully complete commercial testing of new technology and information systems to support new products and services, including voice transmission services; failure to stabilize or reduce the rate of price compression on certain of the company’s communications services; failure to integrate strategic acquisitions and changes in government policies or regulations of India and, in particular, changes relating to the administration of Tata Communications’ industry; and, in general, the economic, business and credit conditions in India. Additional factors that could cause actual results, performance, or achievements to differ materially from such forward-looking statements, many of which are not in Tata Communications’ control, include, but are not limited to, those risk factors discussed in Tata Communications Limited’s Annual Reports.

The Annual Reports of Tata Communications Limited are available at www.tatacommunications.com. Tata Communications is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements.

© 2025 Tata Communications Ltd. All rights reserved.

TATA COMMUNICATIONS and TATA are trademarks or registered trademarks of Tata Sons Private Limited in India and certain countries.

NEW YORK, July 29, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on July 29th

• Stocks are fractionally higher Tuesday morning following another record close on Monday for the S&P 500, though the large-cap index only saw a slight gain during yesterday’s session.
• More than 150 companies will report earnings this week. The week will be headlined by Microsoft, Meta, Amazon, and Apple, which will release quarterly figures and guidance in the coming days.
• The Federal Reserve is in focus as policymakers kick off their latest two-day meeting today. The Central Bank is expected to keep interest rates unchanged when it delivers its latest decision tomorrow.

Opening Bell
Evolent Health (NYSE: EVH) celebrates its 10^th anniversary of listing

Closing Bell
Daiwa Capital Markets celebrates its 60^th anniversary as a registered U.S. broker-dealer.

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2740135/NYSE_Market_Update_July_29.mp4 

PANAMA CITY, July 29, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3 AI company, shared a major update on the Internship Program under its Global TalentX Strategy, launched earlier this year to cultivate the next generation of Web3, AI, and crypto leaders.

Since its debut this February, the initiative has gained significant global traction, attracting over 1,000 applications from aspiring talents across more than 10 countries and 5 continents. As a result, over 100 interns have been successfully onboarded into departments including product development, operations, marketing, research, branding, administration, and human resources.

The TalentX Strategy goes beyond traditional hiring — it is a long-term investment in people, offering real-world experience, hands-on learning, and expert mentorship. This first cohort reflects BingX’s vision for a diverse, future-focused workforce, built to drive the next wave of decentralized innovation and AI-powered technologies.

Vivien Lin, Chief Product Officer at BingX, commented: “The early success of TalentX affirms our belief that tomorrow’s Web3 breakthroughs will come from fresh, global perspectives. We are not just building a team, we are building a generation of thinkers, builders, and leaders who will help redefine the future of crypto and AI. At BingX, we are proud to offer a platform where young talent can thrive, lead, and drive meaningful innovation.”

About BingX 

Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.

For more information, please visit: https://bingx.com/

HOUSTON, July 29, 2025 /PRNewswire/ — Starlab Space LLC announced a strategic partnership with Journey, a multidimensional experience agency, that will help shape the interior and experiential design of the next-generation commercial space station. Journey joins Hilton and Airbus in developing a station environment that elevates how astronauts live and work in orbit.

Journey brings a deep portfolio of globally recognized projects, including the Sphere in Las Vegas, the Empire State Building observatory in New York City and the Sun Princess Dome for Princess Cruises. The agency will be working closely with Hilton, one of the original strategic partners in the Starlab program, designing the Starlab hospitality and crew experience. Journey’s role adds a vital layer of design and experiential innovation, shaping a space that reflects both function and humanity.

“With Starlab, we want to create an intuitive and comfortable environment for astronauts that allows them to fully focus on their mission,” said Tim Kopra, Starlab CEO. “Journey understands how to merge design and technology in a very unique context. Their work will help make Starlab not just a successful operational platform in low-Earth orbit but also an exceptional place to work and live.”

This collaboration focuses on enhancing everyday life in orbit. By combining narrative design, digital infrastructure and spatial layout, Journey will help ensure Starlab functions as both a cutting-edge research platform and a welcoming, livable habitat.

“Our mission is to create multidimensional experiences for the world’s most compelling and ambitious projects,” said Lionel Ohayon, Journey’s Chief Creative Officer & Co-Founder. “We’re applying our decades of design expertise to humanity’s next frontier: space. We couldn’t be more excited to partner with Starlab to bring this world-shifting vision to life.” 

Starlab is targeting launch ahead of the International Space Station’s planned retirement and is designed to support a continuous human presence in orbit. The station will offer research and commercial opportunities for government agencies, academic institutions and private industry worldwide.

About Starlab

Starlab Space is a U.S.-led, global joint venture among Voyager Technologies, Airbus, Mitsubishi Corporation, MDA Space and Palantir Technologies, with strategic partners including Hilton, Northrop Grumman and The Ohio State University. Starlab is developing a next-generation, AI-enabled commercial space station, aiming to ensure continued human presence in low-Earth orbit and a seamless transition of microgravity science and research alongside the retirement of the International Space Station. Starlab’s advanced, user-driven design and robust capabilities make it a premier platform for scientific discovery and technological advancement in space. 

For more information, visit starlab-space.com.

About Journey

Journey is a global design and innovation agency shaping the future through multidimensional experiences (MDX) that connect people, brands, and culture. Journey’s layered MDX approach crafts story-driven, sensory-rich engagement across physical, immersive, digital, and virtual spaces—fuelled by creative and technological innovation. Born from a legacy of pioneering studios, Journey blends strategic thinking with deep creative expertise to deliver solutions across industries. Journey fuels growth and forges lasting value for audiences and partners by creating meaningful experiences that resonate across every dimension of human interaction.

Visit www.journey.world for more information.

Rendering of Starlab space station in orbit above Earth

SAN JOSE, Calif., July 29, 2025 /PRNewswire/ — Reallusion announces the open beta of AI Render, a completely free plugin that bridges Reallusion’s intuitive 3D software—including Character Creator and iClone—with ComfyUI, the open-source, node-based interface widely regarded as the gold standard for customizable AI visual generation.

Reallusion AI Render for iClone & Character Creator with ComfyUI Integration, Available in Open Beta

AI Render enables the re-visualization of stylized 3D characters and scenes through a streamlined pipeline that supports both rapid visual exploration and consistent AI-driven re-imaging for stills and video production.

As a leading developer of real-time 3D animation tools, Reallusion empowers professionals and enthusiasts alike to step confidently into the future of 3D media creation.

The AI Render Open Beta is now live and available on the Reallusion Official Forum, where users can download the plugin, access tutorials, and connect with the development team and the active community.

Key Features

Seamless 3D & AI Integration

The foundation of AI Render is built on Reallusion’s custom node for ComfyUI, enabling a seamless two-way connection between your AI workflow and Reallusion’s 3D tools. It transfers full 3D scene data — including character poses, lighting, and camera angles — directly from iClone and Character Creator, with no technical setup required.

This integration is fully embedded into the intuitive UI of iClone and CC, allowing you to work visually and interactively while generating AI content with precision and creative control.

22 Built-In Style Presets

AI Render includes 22 professionally tuned presets across three categories: Realistic, 3D stylized, and 2D illustration. Each preset comes with optimized ControlNet settings, prompt templates, and rendering configurations for fast, consistent results.

Prompt + Reference-Based Customization

Users can guide AI results using traditional text prompts or reference images. The plugin supports IP Adapter, which allows AI to match the style and tone of any uploaded image without the need for complex prompt engineering.

Precise 3D ControlNet Guidance

Unlike AI tools that rely on 2D estimations, AI Render uses 3D-driven ControlNet inputs for stable, accurate generation across frames:

• Depth: Spatial layering and facial accuracy
• Pose: Reliable skeletal tracking, even with occlusion
• Normal: Surface lighting and shading
• Edge (Canny): Clean outlines for stylized renders

All inputs are generated directly from real-time 3D environments built in iClone and Character Creator, using Reallusion’s library of over 13,000 easily searchable, drag-and-drop assets, including characters, motions, lighting, and cameras. This makes it fast and intuitive to build structured scenes that provide AI with the consistent, frame-by-frame guidance it needs.

LoRA Dataset Creation for Character Consistency

To maintain consistent character appearances across AI videos, LoRA (Low-Rank Adaptation) training is supported. AI Render does not perform training directly but enables rapid dataset creation in iClone using batch rendering, pose libraries, and automated camera paths. Reallusion will provide project templates to assist in generating LoRA training sets for unique characters.

AI-Powered Storytelling for Character IP

AI Render is ideal for creators developing original IP characters. With Character Creator and iClone, users can design fully rigged, production-ready characters. AI Render extends their use into AI-generated movies, commercials, and stylized storytelling; all the while maintaining consistent look, expression, and style.

This isn’t just AI for visuals, your characters can now appear in AI-generated content with the continuity and expressiveness of a real actor.

Compatibility and Requirements

System Requirements:

• Operating System: Windows 10 or higher
• GPU: NVIDIA RTX 30 series (8GB minimum), AMD GPUs are not supported
• Storage: ~80 GB recommended for full model installation

• iClone 8.54 or Character Creator 4.54 (Note: Full versions are required. Trial versions are not supported.)

AI Render runs locally and is designed to work with:

• Stable Diffusion 1.5, Wan2.1 Fun 1.3B Control and Wan2.1 VACE 1.3B (default local models)
• Flux, HiDream, and FusionX are supported, but they require a more powerful hardware setup or must be run on a cloud GPU platform

Reallusion is also preparing cloud integration options for major platforms, such as RunPod and RunComfy, allowing users with modest hardware to generate high-resolution, commercial-quality outputs.

Community Challenge: Win Character Creator 5

To celebrate the launch, Reallusion is hosting a public AI Makeover Challenge from July 24 to August 22, 2025. Participants can transform their Character Creator 4 (CC4) characters using AI Render and submit images or videos for a chance to win a free copy of Character Creator 5 (CC5).

Get Started Now!

Learn more about the features of the AI Render plugin and the limited-time event in the full announcement. Visit the Reallusion Official Forum now to download AI Render, follow setup guides, and connect with the community!

This move strategically enhances Quasar’s ties to Singapore’s MedTech ecosystem and facilitates closer collaboration with global partners

SINGAPORE, July 29, 2025 /PRNewswire/ — Quasar Medical, a global leader in manufacturing interventional and minimally invasive medical devices, announced today the opening of its Global Headquarters in Singapore. This milestone marks the company’s continued growth and reinforces its commitment to advancing medical innovation worldwide.

Quasar has operated out of Hong Kong since its founding in 1988 and will continue to maintain comprehensive business operations there as part of its global presence. Relocating the headquarters from Hong Kong to Singapore strategically positions the company at the heart of Asia’s MedTech ecosystem—a region at the forefront of medical technology and healthcare innovation. The expanded two-floor facility, acquired in 2021, adds 7,000 square feet to its existing 35,000 square feet and is designed to foster collaboration, accelerate innovation, and meet the needs of customers worldwide.

“Establishing our Global Headquarters in Singapore reflects our commitment to operating where innovation thrives,” said Alex Wallstein, CEO of Quasar Medical. “Singapore is a major MedTech hub, hosting leading research institutions, top talent, and vital partners. This move will accelerate our ability to deliver advanced catheter technologies that shape the future of minimally invasive care while strengthening our collaboration with customers.”

With enhanced extrusion, braiding, balloon manufacturing, advanced assembly automation, and cutting-edge inspection systems, the new headquarters strengthens Quasar’s ability to deliver high-volume production, customized catheter solutions, exceptional quality control, and greater supply chain flexibility.

Serving as the hub for global operations, the Singapore headquarters is supported by a local team of 180 employees across engineering, operations, program management, quality, and select corporate functions. The headcount is expected to exceed 300 within three years, based on Quasar’s ambitious growth strategy and supported by Singapore’s expanding talent pool. The Singapore facility demonstrates Quasar’s sustained commitment to the region and its strategic vision for the future of medical device manufacturing.

“This move marks an exciting new chapter for Quasar in Singapore,” said Erik Trip, Site Leader. “We are expanding advanced operations, growing a strong local team, creating career opportunities, and positioning Quasar as an employer of choice within Singapore’s MedTech community.”

“Singapore welcomes Quasar Medical’s decision to establish its Global Headquarters and expand its manufacturing and innovation capabilities here. This investment reinforces Singapore’s position as a global MedTech hub where healthcare businesses can tap into our ecosystem and skilled workforce to develop and produce quality medical devices for the world. We look forward to partnering with Quasar Medical in delivering medical devices that improve lives while creating good job opportunities for Singaporeans,” said Ms. Cindy Koh, Executive Vice President, Singapore Economic Development Board.

The new headquarters reflects the remarkable progress Quasar has achieved over its 38-year journey and serves as a foundation for the next chapter—connecting people, partners, and ideas to deliver medical device solutions that improve lives worldwide.

Quasar Medical is a global Contract Development and Manufacturing Organization (CDMO) delivering end-to-end solutions for interventional and minimally invasive medical devices. With 10 global facilities and over 4,200 employees across Asia, North America, and Europe, Quasar specializes in catheter systems, balloon technologies, micro-EM sensors, and complex assemblies, delivering cost-effective scalability and unmatched speed to market. Headquartered in Singapore, the company provides fully integrated device solutions spanning design, prototyping, and scalable manufacturing. Quasar operates under ISO 13485:2016 and cGMP standards, serving leading medical device OEMs and innovators worldwide. For more information, visit www.quasarmedical.com 

PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ — Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Annual Meeting to be held in Paris, France from September 17-20, 2025.

AD, a chronic, heterogeneous, inflammatory disease characterized by skin redness, pruritus, and pain, is driven by skin barrier disruption and T-cell-dependent inflammatory pathways. Expansion of OX40R+ pathogenic T cells leads to T-cell imbalance, a root cause of inflammatory diseases including AD.

Title: Efficacy & Safety of OX-40 Receptor Targeting with Rocatinlimab in Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3 ROCKET-IGNITE Trial

Presenter: Emma Guttman-Yassky, MD, PhD

Date: Friday, September 19^th
Time: 4:40 – 4:50 pm CEST
Session: FC 08 Atopic Dermatitis
Location: Paris Convention Centre, Pavillon 7.3, Room W05-W06

About the ROCKET Phase 3 Program
ROCKET is a comprehensive, global Phase 3 clinical trial program comprised of eight studies intended to establish the safety and efficacy profile of rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) as well as multiple dosing regimens.

About Moderate to Severe Atopic Dermatitis
Atopic dermatitis, the most common form of eczema, is a chronic inflammatory disease that causes excessively dry, itchy skin that can be painful. People with moderate to severe atopic dermatitis experience chronic symptoms, intensified by unpredictable flare-ups that can be painful and disruptive to everyday life. More than half of these patients report severe itching, leading to repeated scratching which can cause the skin to thicken and become vulnerable to infection. Atopic dermatitis (all severities) affects 15-20% of children and up to 10% of adults. T-cell imbalance is a root cause of atopic dermatitis, contributing to clinical manifestations including the disease’s recurring, unpredictable symptoms.

About Rocatinlimab
Rocatinlimab is an anti-OX40 human monoclonal antibody being investigated for the treatment of moderate to severe atopic dermatitis. Rocatinlimab has the potential to be the first and only T-cell rebalancing therapy that inhibits and reduces pathogenic T cells by targeting the OX40 receptor. OX40 is a co-stimulatory receptor responsible for driving systemic and local inflammatory responses in atopic dermatitis and other conditions. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with atopic dermatitis and are critical in the disease pathophysiology.

Rocatinlimab is also being studied for prurigo nodularis, moderate to severe uncontrolled asthma and potentially other conditions where T-cell imbalance is a root cause of inflammation. The initial antibody was discovered in collaboration between Kyowa Kirin and La Jolla Institute for Immunology.

Rocatinlimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by the U.S. FDA or any other regulatory authority.

About Kyowa Kirin
Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/.   

Amgen and Kyowa Kirin Collaboration
On June 1, 2021, Kyowa Kirin and Amgen entered into an agreement to jointly develop and commercialize rocatinlimab. Under the terms of the agreement, Amgen will lead the development, manufacturing, and commercialization for KHK4083/AMG 451 for all markets globally, except Japan, where Kyowa Kirin will retain all rights. If approved, the companies will co-promote the asset in the United States and Kyowa Kirin has opt-in rights to co-promote in certain other markets including Europe and Asia.

CONTACT:

Kyowa Kirin
Hiroki Nakamura: Japan
Corporate Communications Department
media@kyowakirin.com

Subrenie Thomas-Smith: North America
Sr. Director, R&D Patient Engagement & Communications
subrenie.thomas-smith.8c@kyowakirin.com